Hemorrhagic Fever Epidemiology Forecast 2025-2034

Viral hemorrhagic fevers collectively impose a significant global health burden, particularly across tropical and subtropical regions. Despite their rarity in high-income countries, globalization, climate shifts, and increased human-animal interaction have elevated their pandemic potential. The hemorrhagic fever epidemiology forecast by Expert Market Research reveals that warming climates and vector adaptation have extended dengue and CCHF into previously non-endemic regions such as Southern Europe, Central Asia.

Hemorrhagic Fever Epidemiology Forecast Report Coverage

Expert Market Research's “Hemorrhagic Fever Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of hemorrhagic fever. It projects the future incidence and prevalence rates of hemorrhagic fever cases across various populations. The study covers age, gender, and type as major determinants of the hemorrhagic fever population. The report highlights patterns in the prevalence of hemorrhagic fever over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on hemorrhagic fever epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Hemorrhagic Fever Understanding: Disease Overview

Viral hemorrhagic fevers (VHFs) are a group of severe, often life-threatening diseases caused by RNA viruses such as Ebola, Lassa, Dengue, and Hantavirus. These infections damage vascular integrity, leading to bleeding, organ failure, and shock. Transmission occurs through vectors or contact with infected bodily fluids, depending on the virus. VHFs predominantly affect tropical and subtropical regions and are associated with outbreaks of high mortality. Early symptoms mimic flu-like illness, progressing rapidly to multi-organ dysfunction without prompt supportive intervention.

Hemorrhagic Fever Epidemiology Perspective

The hemorrhagic fever epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the hemorrhagic fever epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for hemorrhagic fever and their trends. The hemorrhagic fever detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Dengue hemorrhagic fever (DHF) is the most prevalent hemorrhagic fever globally. It is endemic in more than 120 countries, including most of Latin America, Southeast Asia, and parts of Africa.
• In 2024, over 7.6 million dengue cases were reported globally, including 3.4 million confirmed cases, with over 16,000 severe cases and more than 3,000 deaths. It affects both genders, with no significant gender-based differences in incidence.
• Approximately 10,000-15,000 cases of Crimean-Congo hemorrhagic fever (CCHF) occur annually worldwide, though up to 88% may be subclinical or unrecognized due to limited surveillance.
• Historically, 60,000-150,000 cases of Hemorrhagic Fever with Renal Syndrome (HFRS) were reported annually, predominantly in Asia, with a fatality rate ranging from 0.1% to 15%.

Country-wise Hemorrhagic Fever Epidemiology Segment

The hemorrhagic fever epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

In India, dengue fever remains the most significant hemorrhagic fever, with the National Centre for Vector Borne Diseases Control (NCVBDC) reporting 233,519 cases and 297 related deaths in 2024. While other hemorrhagic fevers such as Crimean-Congo hemorrhagic fever (CCHF) and hemorrhagic fever with renal syndrome (HFRS) have not been documented, dengue continues to pose a major public health challenge. Focused surveillance, vector control strategies, and public awareness campaigns are essential to reduce morbidity and mortality nationwide.

Hemorrhagic Fever: Treatment Overview

Treatment for hemorrhagic fever primarily involves supportive care to maintain hemodynamic stability and organ function. The management includes fluid replacement, electrolyte correction, oxygen therapy, and blood transfusions as needed. Antiviral agents like ribavirin may benefit certain types such as Lassa or Crimean-Congo fever. For Ebola and similar infections, monoclonal antibody therapies and vaccine-based prevention have shown improved outcomes. Vector control, quarantine measures, and vaccination campaigns are essential in outbreak prevention. Rapid diagnosis and containment remain key to reducing morbidity and mortality.

Key Questions Answered

• What are the key findings of hemorrhagic fever epidemiology in the 8 major markets?
• What will be the total number of patients with hemorrhagic fever across the 8 major markets during the forecast period?
• What was the country-wise hemorrhagic fever epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of hemorrhagic fever during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of hemorrhagic fever during the forecast period of 2025-2034?
• What are the currently available treatments for hemorrhagic fever?
• What are the disease risks, signs, symptoms, and unmet needs of hemorrhagic fever?

Scope of the Hemorrhagic Fever Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of hemorrhagic fever based on several factors.
• Hemorrhagic Fever Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The hemorrhagic fever report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.